X

Tim Boreham

Tim is one of Australia’s best-known small-cap share analysts and business journalists. He has more than 30 years of experience writing for major business publications. He is known for the highly-respected Criterion investment column which ran for many years in The Australian newspaper.

CRITERION: Has this stock been given the right royal treatment it deserves?

Mayur stock did little in the wake of a well-flagged funding announcement, but the stock has surged a sub-lime 25…

CRITERION: Got a chip on your shoulder over missing Nvidia? Here’s the latest intel on AI stocks

The hunt for the most local AI fast follower continues, with investors flocking to a $1.3 billion capital raising from…

Dr Boreham’s Crucible: Is Breastest the bestest breast test? Bcal’s close to finding out

Bcal is happy to use Australia as the springboard for what will be the country’s first blood-based breast cancer assay…

CRITERION: Keep it on the downlow but it’s possible successful IPOs are… back?

According to Criterion’s very reliable sources, six companies have listed in 2024 to date... and only two of them are…

CRITERION: Two ASX PFAS success stories? Must be something in the water…

Dubbed the ‘new asbestos’, PFAS is the collective name for a group of man-made chemicals used in industrial and applications.

CRITERION: If reports of Zuckerberg hoarding gooooooold are true… should you?

There are reports that “millionaires and elites” (including Mark 'Meta' Zuckerberg) are hoarding the yellow stuff, with small-denomination bars especially…

Dr Boreham’s Crucible: Universal Biosensors chief John Sharman is exasperated about investor indifference

When your columnist caught up with Universal Biosensors chief John Sharman early last Tuesday, he was exasperated about investor indifference…

CRITERION: Time to get on-board and barrack for Team Tassie stocks? The devil’s in the detail

These days, Tasmania’s economic renaissance is more about wooing visitors with fine cheeses and boutique whiskies than whining chainsaws.

CRITERION: Are profits on the horizon for the ASX’s aged care orphan?

Regis Healthcare shares already have soared 170% over the past year, partly on the back of increased government support for…

Dr Boreham’s Crucible: Vitura Health is the tall poppy in a paddock of weed

Formerly known as Cronos Australia, Vitura (ASX:VIT) is in the rare position of producing revenues, profits … and dividends.

CRITERION: It’s a takeover fire sale on the ASX. These companies are on the specials rack

Barely a day has gone by without a fresh takeover offer for an ASX-listed company, with suitors targeting both large…

Dr Boreham’s Crucible: Does Clinuvel’s investor value run deeper than ‘it just makes Scenesse’?

Clinuvel might be in a funk share-price wise, but its multiple clinical programs would seem to have a decent chance…

CRITERION: Hard rock is so passé; it’s brine’s time in the sun, lithium lovers

Amid complex price dynamics, the owners of two brine-based projects are testing the waters for big-ticket funding.

CRITERION: The spotlight’s on earnings season and so far these divas have crushed it

The corporate reporting season gig is not done and dusted but with only a few days to go we all…

Dr Boreham’s Crucible: Don’t have a heart attack, CSL’s profit-making ability is in the blood

CSL may have bled this week, but our Mr In Between view is that a steady flow of new products…

CRITERION: Dumped these education stocks lately? That’ll lern ya.

Education stocks are looking smart. I *clap* don't *clap* want *clap* to *clap* have *clap* to *clap* tell *clap* you…

CRITERION: Thinking of risking a finger on a falling knife? Sometimes they come back…

While there’s no firm rule, the shares of established, profitable entities tend to recover – and sometimes quickly.

Don't be the last to know

  • By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.